Nano X Imaging Ltd Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.20 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $0.66Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $52M Enterprise Value $6M Shares Outstanding 78.6M diluted Next Earnings Date19 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Nano-X Imaging Ltd. (NNOX) is transitioning from a pre-commercial technology developer to a commercial-stage medical imaging platform. While the company has achieved significant regulatory milestones—including FDA 510(k) clearances for its Nanox.ARC, Nanox.ARC X, and the cloud-enabled TAP2D image enhancement software—it faces severe financial and operational headwinds. The company reported a heavy net loss of $75.0 million for FY 2025, accompanied by substantial going-concern doubts and a high cash burn rate. To address these issues, management has initiated a major restructuring, closing its South Korean chip manufacturing facility (resulting in a $17.5 million impairment charge in Q4 2025) and shifting to an outsourced production model. Although recent distribution agreements (such as the 300-system framework with Howard Technology Solutions and entries into Peru and Argentina) signal commercial momentum, the combination of high execution risk, ongoing litigation, and leadership transitions warrants a cautious 'Hold' recommendation until outsourced manufacturing efficiency and cash-flow stabilization are demonstrated. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.00 Mean target$5.13 High · most bullish analyst$7.40 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case is triggered by prolonged delays in outsourced chip manufacturing, leading to supply chain bottlenecks and slower-than-expected system deployments. High cash burn persists, forcing aggressive dilution under the ATM facility. Additionally, the class-action lawsuit results in substantial legal liabilities or settlements, and the transition to a new CFO disrupts financial operations, causing the stock to test historical lows. Base CaseCentral scenario The base case assumes that Nanox successfully executes its outsourced manufacturing transition, stabilizing production costs and reducing cash burn. Commercial deployment of the Nanox.ARC systems proceeds steadily under regional U.S. distribution agreements and international partnerships, allowing the company to approach its FY 2026 revenue target of $35 million. However, profitability remains elusive over the next 2-3 years, and the company continues to rely on its $100 million at-the-market equity facility, leading to moderate shareholder dilution. Bull CaseUpside scenario The bull case centers on Nano-X successfully transitioning from a pre-profitability hardware developer to a high-margin, recurring-revenue medical imaging network. By leveraging its low-cost Nanox.ARC digital X-ray system (utilizing cold-cathode technology) under an 'imaging-as-a-service' subscription model, the company can scale deployments globally. If these installed systems successfully convert into active clinical workflows, the high-margin software, AI diagnostics, and teleradiology layers can drive rapid, high-margin revenue growth that far outpaces the hardware footprint alone. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |